{"id":"fsc","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Hoarseness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FSC typically refers to a fixed-dose combination of fluticasone propionate (a corticosteroid) and salmeterol (a long-acting beta-2 agonist), commonly known by the brand name Seretide/Advair. The fluticasone reduces airway inflammation while salmeterol provides bronchodilation through beta-2 receptor agonism. This combination addresses both the inflammatory and obstructive components of chronic respiratory disease.","oneSentence":"FSC is a combination therapy that works through dual mechanisms to treat respiratory and inflammatory conditions.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:37.938Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT05765773","phase":"PHASE2","title":"An Open Comparative Study of the Effectiveness and Incomparable Study of the Immunogenicity and Safety of the Vaccine (CoviVac) for Adults Aged 60 Years and Older","status":"COMPLETED","sponsor":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products","startDate":"2021-07-01","conditions":"Corona Virus Infection, Vaccine, COVID-19","enrollment":200},{"nctId":"NCT05792449","phase":"NA","title":"Tele-rehabilitation Program: An Innovative and Sustainable Early Intervention Service for Children With Autism Spectrum Disorders","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2019-01-07","conditions":"Autism Spectrum Disorder","enrollment":200},{"nctId":"NCT05407142","phase":"PHASE3","title":"An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac)","status":"UNKNOWN","sponsor":"Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products","startDate":"2021-07-07","conditions":"Coronavirus Infections, Vaccine","enrollment":29000},{"nctId":"NCT05654766","phase":"","title":"Assesment of the Functional Activity of Platelets for the Differential Diagnosis of Thrombocytopathies","status":"UNKNOWN","sponsor":"Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus","startDate":"2023-01-02","conditions":"Immune Thrombocytopenia, Thrombocytopathy, Acute Leukemia","enrollment":200},{"nctId":"NCT03815786","phase":"NA","title":"NATURE 3.1_New Approach for the Reduction of REnal Uremic Toxins","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari","startDate":"2017-05-24","conditions":"Chronic Kidney Diseases, Healthy","enrollment":50},{"nctId":"NCT02924688","phase":"PHASE3","title":"A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-10-13","conditions":"Asthma","enrollment":2436},{"nctId":"NCT04403906","phase":"NA","title":"Somerset and South Essex Coronavirus Antigen Testing","status":"UNKNOWN","sponsor":"Somerset NHS Foundation Trust","startDate":"2020-06","conditions":"COVID, SARS-CoV 2","enrollment":200},{"nctId":"NCT03946176","phase":"NA","title":"NATURE 3.2_New Approach for the Reduction of REnal Uremic Toxins","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari","startDate":"2017-05-17","conditions":"Hemodialysis","enrollment":16},{"nctId":"NCT00118716","phase":"PHASE4","title":"A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-12-23","conditions":"Bronchospasm, Activity/Exercise Induced Bronchospasm","enrollment":248},{"nctId":"NCT00984659","phase":"PHASE4","title":"Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":366},{"nctId":"NCT01462344","phase":"PHASE4","title":"6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-17","conditions":"Asthma","enrollment":6250},{"nctId":"NCT01475721","phase":"PHASE4","title":"SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-11-18","conditions":"Asthma","enrollment":11751},{"nctId":"NCT01890863","phase":"PHASE1","title":"ROTAHALER Device Optimization Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-08-05","conditions":"Asthma","enrollment":36},{"nctId":"NCT01110200","phase":"PHASE4","title":"Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-04-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":639},{"nctId":"NCT01817764","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":707},{"nctId":"NCT01879410","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-06-13","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":700},{"nctId":"NCT01822899","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-04-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":717},{"nctId":"NCT01978145","phase":"PHASE3","title":"A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Fluticasone Propionate/Salmeterol (FSC) 250/50 Microgram (mcg) Through a Capsule-Based Inhaler and a Multi-Dose Inhaler Administered Twice Daily (BID) in Adults With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-11-14","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":665},{"nctId":"NCT02257372","phase":"PHASE4","title":"A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":236},{"nctId":"NCT01331694","phase":"","title":"Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":76130},{"nctId":"NCT01381406","phase":"","title":"Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate/Salmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":3333},{"nctId":"NCT01337336","phase":"","title":"Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1},{"nctId":"NCT01978119","phase":"PHASE3","title":"A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol (FSC) 250/50 Microgram (mcg) Twice Daily (BID) in Adults and Adolescents With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-11-06","conditions":"Asthma","enrollment":124},{"nctId":"NCT01381458","phase":"","title":"Risk of Re-Hospitalization in Patients With Chronic Obstructive Pulmonary Disease (COPD) Post Exacerbation","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1936},{"nctId":"NCT01387178","phase":"","title":"Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":22223},{"nctId":"NCT01395875","phase":"","title":"Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2849},{"nctId":"NCT00296491","phase":"PHASE4","title":"Study Of Allergic Rhinitis In Patients Who Also Have Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-09","conditions":"Asthma","enrollment":725},{"nctId":"NCT00452348","phase":"PHASE4","title":"A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05","conditions":"Asthma","enrollment":628},{"nctId":"NCT00452699","phase":"PHASE4","title":"A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05","conditions":"Asthma","enrollment":621},{"nctId":"NCT00920959","phase":"PHASE3","title":"Advair Pediatric Once-Daily","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-11","conditions":"Asthma","enrollment":908},{"nctId":"NCT00920543","phase":"PHASE4","title":"GSK BHR Study (Sont)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-02","conditions":"Asthma","enrollment":464},{"nctId":"NCT01324362","phase":"PHASE4","title":"GSK BHR Study (Sont - Second Study)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-01","conditions":"Asthma","enrollment":446},{"nctId":"NCT02842112","phase":"","title":"Higher Percentage of CD34+ CD38- Cells Detected by Multiparameter Flow Cytometry From Leukapheresis Products Predicts Unsustained Complete Remission in Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2013-01","conditions":"Acute Myeloid Leukemia","enrollment":123},{"nctId":"NCT00385463","phase":"NA","title":"Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Receiving Advair Diskus or Placebo","status":"WITHDRAWN","sponsor":"Creighton University","startDate":"2006-04","conditions":"Asthma, Seasonal Allergic Rhinitis","enrollment":""},{"nctId":"NCT01921127","phase":"","title":"Comparative Effectiveness of Symbicort vs. Advair Among COPD Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-08","conditions":"COPD","enrollment":3000},{"nctId":"NCT00411372","phase":"PHASE3","title":"Shortness Of Breath Questionnaire Validation Study","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2006-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":""},{"nctId":"NCT02218762","phase":"PHASE1","title":"A Study in Patients With Moderate Asthma to Compare Pharmacokinetics and Pharmacodynamic Effects of Fluticasone Propionate and Salmeterol Delivered Via the ROTAHALER® Inhaler Relative to the DISKUS® Inhaler","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2014-10","conditions":"Asthma","enrollment":""},{"nctId":"NCT01623544","phase":"","title":"Asthma Comparative Effectiveness Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-06","conditions":"Asthma","enrollment":6086},{"nctId":"NCT00559312","phase":"NA","title":"The Effect of Fluticasone/Salmeterol Combination on Exertional Breathlessness in Patients With Mild COPD","status":"COMPLETED","sponsor":"Queen's University","startDate":"2007-12","conditions":"COPD","enrollment":18},{"nctId":"NCT00864812","phase":"PHASE4","title":"Clinical Outcomes of Tiotropium Plus Fluticasone Propionate/Salmeterol Compared With Tiotropium for Chronic Obstructive Pulmonary Disease (COPD) in Korea","status":"COMPLETED","sponsor":"The Korean Academy of Tuberculosis and Respiratory Diseases","startDate":"2009-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":509}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"DISTURBANCE IN ATTENTION"},{"count":1,"reaction":"DRUG INTERACTION"},{"count":1,"reaction":"HYPERKALAEMIA"},{"count":1,"reaction":"HYPOTENSION"},{"count":1,"reaction":"MALAISE"},{"count":1,"reaction":"PRODUCT CONTAMINATION CHEMICAL"},{"count":1,"reaction":"PRODUCT QUALITY ISSUE"},{"count":1,"reaction":"PRODUCT SUBSTITUTION ISSUE"},{"count":1,"reaction":"RENAL FAILURE ACUTE"},{"count":1,"reaction":"SYNCOPE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Advair (tm)"],"phase":"phase_3","status":"active","brandName":"FSC","genericName":"FSC","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FSC is a combination therapy that works through dual mechanisms to treat respiratory and inflammatory conditions. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}